The neurotrophins neurotrophin-3 (NT-3), brain-derived growth factor (BDNF) and nerve growth factor (NGF) bind to the p75 receptor, but each neurotrophin also binds a more selective Trk receptor (e.g. TrkA-NGF and TrkC-NT-3). The biochemical signals following engagement of either Trk or p75 with ligands are well understood, but long-term biological outcomes (trophic, proapoptotic or differentiative) remain unclear because they are cell/tissue specific. For example, Trk receptors are usually trophic but when overexpressed they can be proapoptotic in neuroblastomas and medulloblastomas. We hypothesized that coexpression of Trk and p75 receptors may lead to cross-regulation of signals and different biological outcomes; and used receptor-selective ligands to study crossregulation by these receptors. We show that in the absence of Trk activation, expression of TrkC is permissive of p75 trophic and differentiation signals induced by p75 ligands, whereas expression of TrkA abolishes trophic and differentiation signals induced by p75 ligands. In contrast, in the presence of Trk activation, p75 ligands can regulate TrkA-mediated survival and TrkC-mediated differentiation. Therefore, a complex homeostasis of p75-selective and Trk-selective signals may determine the fate of cells expressing both receptors.
Introduction
The neurotrophins nerve growth factor (NGF), brainderived neurotrophic factor (BDNF), Neurotrophin-3 (NT-3) and Neurotrophin-4 (NT-4) are a family of growth factor proteins that function by binding to two different classes of receptors, the common p75 receptor and the selective Trk family of tyrosine kinase receptors .
All the mature neurotrophins (NGF, BDNF) bind the p75 receptor with relatively low affinity (K d 10 À9 m), although mature NT-3 and pro-NGF can bind p75 with high affinity (Dechant et al., 1997; Lee et al., 2001) . In contrast, Trks are bound more selectively and with relatively high affinity (K d 10 À11 M). NGF binds TrkA, NT-3 binds TrkC preferentially, and also binds TrkA and TrkB with lower affinity, and BDNF binds TrkB.
Neurotrophin-induced Trk signal transduction involves trophic (growth/survival) responses via MAPK and Akt, whereas PLC-g and FRS-2 are obligatory for differentiation (Kaplan and Stephens, 1994; Meakin et al., 1999) . The p75 receptor is a member of the TNF receptor superfamily (Bredesen and Rabizadeh, 1997; Chao et al., 1998b) .
Studies of neurotrophin receptor biology are challenging because of the complex physical and functional interactions that take place between ligands and receptors (Bibel et al., 1999; Zaccaro et al., 2001) , and also because the biological outcomes vary sometimes in seemingly opposite directions and include trophic growth/survival, apoptotic death and neuritogenic differentiation in a cell/tissue-specific manner (Casaccia-Bonnefil et al., 1996; Bamji et al., 1998; Rabizadeh et al., 1999) . As a clear example, the Trks (Yamashiro et al., 1996; Brodeur et al., 1997; Kramer et al., 1997) and the p75 receptors (Frade and Barde, 1998) can either rescue cells from apoptosis or lead to apoptosis; these effects can be ligand-dependent or -independent (Bredesen and Rabizadeh, 1997; Chao et al., 1998a) ; and may depend on cell cycle (Urdiales et al., 1998) .
It is important to consider that each of the receptors (Trk and p75) can transduce signals independently; and therefore a homeostatic balance must be achieved to regulate signal transduction. For example, anti-p75 mAb MC192 binding to p75 acts as a functional ligand that can enhance TrkA activation in the absence of NGF (Maliartchouk and , while BDNF binding to p75 acts as a functional ligand to reduce TrkA activation (MacPhee and Barker, 1997) , in an affinity-independent manner. In these and related (Vesa et al., 2000) studies, the only biological outcome reported pertained to trophic effects through TrkA or TrkB. Neuritogenic effects were not reported, and no studies have been performed with TrkC. 
Results
Selective p75 ligands regulate trophic survival differently in TrkA-versus TrkC-expressing cells Cells undergo apoptotic death when cultured in serumfree medium (SFM). NGF protects TrkA þ cells, while NT-3 protects TrkC þ cells from apoptotic death in SFM. Neurotrophic protection is dose dependent, with 2 nm NGF or NT-3 affording optimal protection (standardized as 100%), whereas 50 pm NGF or NT-3 protects B50% (Table 1 , rows 1-5).
In TrkA þ p75 þ þ þ cells, saturating concentrations of the p75 selective ligands mAb MC192 (2 nm) or BDNF (10 nm) had no effect on cell survival (Table 1, rows 6  and 7) . However, MC192 synergistically enhanced the limited survival afforded by 50 pm NGF (Table 1, row 8) and BDNF decreased the survival afforded by 50 pm NGF (Table 1 , row 9). These data reproduced previous reports (MacPhee and Barker, 1997; Maliartchouk and Saragovi, 1997) and are entered here as controls.
In contrast, in nnr5-TrkC cells (TrkC þ p75 þ þ þ ) the sole addition of MC192 afforded significant protection from apoptosis (Table 1 , row 6), whereas NGF or BDNF as p75 ligands did not afford protection (Table 1 , rows 1 and 7). The protective effect of MC192 in nnr5-TrkC was not additive with 50 nm NT-3 (Table 1, (MacDonald and Meakin, 1996; Baskey et al., 2002) , but the basis for this remains unclear.
Treatment of nnr5-TrkC cells solely with the p75 ligands NGF (10 nm) or BDNF (not shown) only caused a slightly more differentiated phenotype compared to untreated cells. There was a small increase in axons/cell, but the average axonal length was not affected. It appears as if the nnr5-TrkC cells exposed to NGF or BDNF attempt to differentiate, but the neuritogenic signals are incomplete. For a quantitative summary of data for nnr5-TrkC cells, see Figure 1 , panel m. In TrkC þ cells, sole treatment with the p75 ligand MC192 increased Akt activation; but this occurred with low potency and slow kinetics. A combination of each of the p75 ligands NGF, BDNF or MC192 with suboptimal NT-3 did not significantly alter the kinetics or potency of Akt activation compared to suboptimal NT-3 alone (Figure 2b ).
These data demonstrate that p75 ligands afford a differential regulation of Akt activation in TrkA-and TrkC-expressing cells, consistent with the MTT survival data.
Selective p75 ligands regulate MAPK activation kinetics differently in TrkA-versus TrkC-expressing cells
The MAP kinase plays a crucial role in Trk-dependent cell survival and also in differentiation. MAPK activation was studied as a biochemical correlate of the survival/neuritogenic activity of p75 ligands in TrkA þ ( Figure 3a) and TrkC þ (Figure 3b ) cells.
Optimal concentrations of neurotrophins (2 nm) activated MAPK rapidly and the activation was sustained for longer than 30 0 . Suboptimal neurotrophins (50 pm) activated MAPK with similar kinetics as optimal NGF or NT-3, but the efficacy of activation at each time point was B70% of maximal. In TrkC þ cells, sole treatment with the p75 ligands BDNF, MC192 or NGF did not induce MAPK activation above untreated control (Figures 3a and b) .
However, in TrkA þ cells a combination of MC192 þ 50 pm NGF increased the efficacy of MAPK activation almost to maximal levels (similar to 2 nm NGF). However, a combination of BDNF þ 50 pm NGF did not significantly affect the efficacy of MAPK activation (Figure 3a) . In TrkC þ cells, a combination of each of the p75 ligands with suboptimal NT-3 did not significantly alter the kinetics or potency of MAPK activation either (Figure 3b ). The tyrosine phosphorylation (pTyr) of TrkC ( Figure 4 ) and TrkA (data not shown) were studied to address the hypothesis that p75 ligands can affect the activation kinetics of TrkC and TrkA differently. In nnr5-TrkC cells, optimal (2 nm) NT-3 treatment induced TrkC-pTyr with high potency and with sustained kinetics. Half maximal TrkC-pTyr was seen at B3 0 , maximal TrkC-pTyr by 5 0 and this was sustained for longer than 30 0 . Treatment with suboptimal NT-3 (50 pm) induced TrkC-pTyr with similar kinetics, but the overall efficacy was B65%.
In untreated nnr5-TrkC cells or nnr5-TrkC cells treated singly with the p75 ligands NGF (data not shown), MC192 or BDNF there was insignificant or modest TrkC-pTyr compared to untreated control. Moreover, the p75 ligands added in combination with suboptimal NT-3 did not significantly affect the kinetics or potency of TrkC-pTyr compared with suboptimal NT-3 alone (Figure 4) . Therefore, there is little or insignificant TrkC transactivation by p75 ligands, and these data with nnr5-TrkC contrast fundamentally with published reports on TrkA-expressing cells (data reproduced herein; not shown) (MacPhee and Barker, 1997; Maliartchouk and Saragovi, 1997 ) that p75 ligands strongly regulate TrkA-pTyr and activation, where MC192 upregulates it and BDNF downregulates it.
Discussion
The Trk and p75 receptors, and their interaction with cognate and heterologous ligands play a critical role in deciding the fate of many cells, including tumor cells such as neuroblastoma, medulloblastoma and melanoma.
In the present work, the biological responses of TrkA þ and TrkC þ cells to their respective high-affinity ligands NGF or NT-3 were measured in biological assays by quantifying changes in cell survival profiles and changes in cell shape/neurite extension. Survival and neuritogenesis were correlated biochemically through studies of Trk-pTyr, and in Akt (p-Akt) and MAPK (p-MAPK) activation.
Since nnr5-TrkA and nnr5-TrkC cells express the same density of Trk and p75 proteins on the cell surface, and besides the transfected Trk receptors they are genotypically identical, we can compare the consequences of manipulating p75-signaling pathways using selective ligands.
Results are summarized in Table 2 . We conclude that p75 ligands can regulate ligand-dependent TrkA activity (e.g. TrkA-pTyr, p-Akt, p-MAPK are altered), but do not regulate ligand-dependent TrkC activity (e.g. TrkCpTyr, p-Akt, p-MAPK are not altered). We also conclude that signals from ligand-bound p75 are 
p75 regulation of Trk-dependent and -independent survival activity
Tight regulation of ligand-dependent TrkA activity and poor regulation of ligand-dependent TrkC activity by certain p75 ligands correlate with cell survival when it is studied as the long-term biological outcome. While regulation of ligand-dependent TrkA-mediated survival by p75 ligands had been shown previously (positive by MC192, Maliartchouk and Saragovi, 1997; negative by BDNF, MacPhee and Barker, 1997) , the novel finding that ligand-dependent TrkC-mediated survival is not regulated in the same manner suggests mechanisms unique to each Trk receptor.
In the absence of TrkC ligands, some p75 ligands increase Akt activation and cell survival in TrkC þ cells. This is not so for TrkA þ cells. In the absence of TrkA ligands, the p75 ligands do not induce detectable biochemical signals or biological effects. Akt activation by p75 can be ligand independent in cells lacking Trk expression (Roux et al., 2001) . Our data show that Akt (a question addressed herein) , it is known that in neuronal survival TrkA relies mainly on the PI3K/Akt pathway, but TrkB also requires MAPK activity (Atwal et al., 2000) . Indeed, for TrkA-or TrkCexpressing nnr5 cells, our data suggest that p75 regulation of Trk-survival signals does not involve alterations to the MAPK pathway, because biologically active p75 ligands did not affect MAPK activation significantly.
p75 regulation of Trk-dependent and -independent neuritogenic activity
Nearly a symmetrically opposite picture emerges when neuritogenesis is studied as a long-term biological outcome, compared versus survival. The dichotomy between survival and differentiation is not surprising because it is known that while TrkB and TrkC use similar signaling to regulate survival, these receptors use distinct signaling to regulate target innervation of sensory neurons (Postigo et al., 2002) . Also, a TrkA ligand (Saragovi et al., 1998) and TrkA mutants (MacDonald and Meakin, 1996) that differentially afford survival, but not differentiation, have been reported.
All p75 ligands can increase TrkC-mediated neuritogenesis, while BDNF can decrease TrkA-mediated neuritogenesis. In the absence of Trk ligands, some p75 ligands increase neuritogenesis in TrkC þ cells while having no effect on TrkA þ cells. Increased neuritogenesis occurred without TrkC activation (TrkC-pTyr) above background. Therefore, signaling leading to neuritogenesis by liganded p75 is facilitated by TrkC expression. These data are consistent with a report that neuritogenesis could result when kinase-dead TrkC and p75 are coexpressed (Hapner et al., 1998) . It is likely that direct Akt activation by some p75 ligands in TrkC þ cells causes neuritogenesis. As discussed above for the survival signals, our data suggest that p75 regulation of Trk-mediated differentiation signals does not involve alterations to the MAPK pathway.
Possible signals induced by p75 ligands
In cells expressing p75 and TrkA, NGF can silence AKT through p75 (Ito et al., 2003; Lachyankar et al., 2003) . In contrast, in cells expressing p75 and TrkC certain p75 selective ligands activate Akt leading to cell survival and cellular differentiation. Since the p75 ligands did not induce TrkC-pTyr or MAPK activation in nnr5-TrkC cells, the data suggest that Akt activation may occur through genuine p75 signaling mechanisms independent of TrkC transactivation. If so, this would be distinctive to cells expressing p75 and TrkC.
There are three possible mechanisms by which p75 may afford survival and differentiation. One survival mechanism may involve activation of NF-kB, which can cooperate with Akt-dependent cell survival (Bhakar et al., 1999; Romashkova and Makarov, 1999; Gentry et al., 2000; Sarmiere and Freeman, 2001 ). However, in other systems p75 ligands regulate differentiation and apoptosis via NF-kB pathways Hirata et al., 2001) . A differentiation mechanism may involve ligand-dependent interactions of p75 with RhoA that modulates neurite elongation (Yamashita et al., 2002) . Third, p75 signaling can also regulate differentiation and survival via ceramide-dependent pathways that can be in turn regulated by activated PI-3 kinase (Brann et al., 1999 (Brann et al., , 2002 Schubert et al., 2000; Bilderback et al., 2001) .
While our studies focused on ligand-bound p75 signals and Trk-regulation, it is noteworthy that unbound p75 also regulates ligand-dependent Trk activation (Vesa et al., 2000; Zaccaro et al., 2001) . Moreover, our studies used a single ratio of Trk/p75 density (5000/ 75 000 ratio), but it is known that different receptor ratios can affect ligand-dependent and -independent signaling (Esposito et al., 2001; Yan et al., 2002) .
In summary, these studies demonstrate a homeostatic balance between survival/differentiative and perhaps apoptotic signals mediated by TrkA versus TrkC receptors, and how expression of p75 receptors (liganded or not) modulates Trk signals. Future studies will concentrate on elucidating the p75 signaling mechanisms regulating TrkA and TrkC transactivation, and the mechanism of the corresponding differential cross-regulation of TrkA or TrkC upon p75 signals.
Materials and methods

Cell lines
Rat pheochromocytoma PC12 cells express low levels of rat TrkA and B75 000 p75 receptors per cell (TrkA þ , p75 þ þ þ ). The nnr5 cells are a PC12 variant that lost TrkA expression and NGF responsiveness, but retain equal density of p75 (TrkA 
Ligands
The mAb MC192 is an anti-p75 antibody. MC192 does not block p75 Á NGF interactions, and in fact it increases the affinity of p75 Á NGF about twofold (Mahadeo et al., 1994; Barker, 1998; Hempstead, 2002) . Here, MC192 is used as a p75-receptor-selective ligand because it fulfills the criteria of selectivity, high affinity, saturability, reversibility and functionality. Previously, mAb MC192 was shown to affect TrkAsignaling (MacPhee and Barker, 1997; Maliartchouk and Saragovi, 1997) . NGF is a p75 ligand and a TrkA ligand, but at low concentrations it would bind preferentially to TrkA. NT-3 is a p75 ligand and a TrkC ligand but it can also bind TrkA. In our assays BDNF is a p75 ligand only.
Cell survival assays
Cell survival was measured with the tetrazolium salt reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) and OD readings as described (Maliartchouk and Saragovi, 1997) . Cells were plated in 96-well plates (Falcon, Mississauga, Canada) at B5000 cells/well in protein-free medium (PFHM-II; Life Technologies, Inc.) with 0.2% bovine serum albumin crystalline fraction V (Sigma) (herein termed 'SFM'). The cultures were untreated or were treated with p75-or Trk-selective ligands (or combinations thereof) as indicated for 48 h. Cell viability was quantified afterwards. All assays were repeated at least three independent times, n ¼ 4-6 wells per assay. Percentage of protection was standardized from OD readings relative to optimal neurotrophin (2 nm ¼ 100%). The OD values of untreated cells in SFM (which die by apoptosis) were subtracted.
Kinetics of Trk, Akt and MAPK activation. Cells were washed with PBS and rested in SFM at 371C for 20 min to lower background phosphorylation. The kinetics of activation for each protein (Trk, Akt or MAPK) was followed after treatment of live cells with p75-selective or Trk-selective ligands (or combinations thereof) as indicated, for the various times shown, at 371C. Cells were then washed in ice-cold PBS, lysed in 1% NP-40 detergent lysis buffer with protease inhibitors (Saragovi et al., 1998) and protein concentrations were determined (Bio-Rad Laboratories). Samples were analysed by Western blotting with antiphosphotyrosine (apTyr) antibody 4G10 (Upstate Biotechnology, Inc., Lake Placid, NY, USA), antiphospho-Akt (Ser473) antibody (New England Biolabs) or antiphospho-MAPK (p42/44 thr202/ tyr204) (New England Biolabs). Blots were visualized using the enhanced chemiluminescence system (Perkin-Elmer Life Sciences). Stripping and reblotting membranes with anti-Trk 203 antiserum or antiAkt antiserum confirmed the Trk and Akt identity of the bands seen with a-pTyr and antiphosphoAkt. Coomassie blue staining of gels confirmed equal protein loading. In all cases, at least three independent assays were performed.
Differentiation assays and immunocytochemistry
Cells were plated onto collagen-coated coverslips, and 24 h later they were treated as indicated for an additional 48-96 h. Then, coverslips were washed with PBS, cells were fixed (4% paraformaldehyde in PBS for 20 min at room temperature), permeabilized (10% FCS þ 0.2% Triton X-100 in PBS) and blocked (blocking solution 10% FCS þ 0.1% Triton X-100 in PBS). Cells were immunostained with saturating anti-Thy1 CD90 antibody coupled with fluorescein (FITC) (Pharmingen) in blocking solution for 1 h at room temperature, washed three times with PBS and mounted with immunomount. Neurite extensions were quantified after capturing five different fields on a fluorescent microscope ( Â 40 magnification), in three different slides prepared independently (a total of 15 pictures) for each time point (48, 72, 96 h) . Data are shown graphically as the average number of axons/cell and average axonal length/cell resulting from each treatment or controls, for the 72 h time point. Each figure shown is a representative image from 15 pictures.
Statistical analysis
Data were analysed by Student's t-test with Bonferroni corrections. Statistical significance means Pp0.01.
